Qingqing Cai

32PUBLICATIONS
88CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cellular nervous systemMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 02, 2026
Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.

|Aug 27, 2026
Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.

|Jun 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

|Jun 10, 2026
TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial.

|Mar 30, 2026
LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial.

Jun Cai, Baitian Zhao, Dongmei Ji

|Mar 28, 2026
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

Yuchen Zhang, Man Nie, Yi Cao

Pageof 6

Frequent Collaborators

5 joint publications

Yi Xia

5 joint publications

Yuchen Zhang

5 joint publications

Zhiming Li

5 joint publications

Panpan Liu